Indications and Purposes
| 1 Indications And Usage Tazverik Is A Methyltransferase Inhibitor Indicated For The Treatment Of: Adults And Pediatric Patients Aged 16 Years And Older With Metastatic Or Locally Advanced Epithelioid Sarcoma Not Eligible For Complete Resection. ( 1.1 ) Adult Patients With Relapsed Or Refractory Follicular Lymphoma Whose Tumors Are Positive For An Ezh2 Mutation As Detected By An Fda-Approved Test And Who Have Received At Least 2 Prior Systemic Therapies. ( 1.2 ) Adult Patients With Relapsed Or Refractory Follicular Lymphoma Who Have No Satisfactory Alternative Treatment Options. ( 1.2 ) These Indications Are Approved Under Accelerated Approval Based On Overall Response Rate And Duration Of Response. Continued Approval For These Indications May Be Contingent Upon Verification And Description Of Clinical Benefit In A Confirmatory Trial(S). 1.1 Epithelioid Sarcoma Tazverik Is Indicated For The Treatment Of Adults And Pediatric Patients Aged 16 Years And Older With Metastatic Or Locally Advanced Epithelioid Sarcoma Not Eligible For Complete Resection. This Indication Is Approved Under Accelerated Approval Based On Overall Response Rate And Duration Of Response [See Clinical Studies ( 14.1 )]. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In A Confirmatory Trial(S). 1.2 Relapsed Or Refractory Follicular Lymphoma Tazverik Is Indicated For The Treatment Of Adult Patients With Relapsed Or Refractory (R/r) Follicular Lymphoma (Fl) Whose Tumors Are Positive For An Ezh2 Mutation As Detected By An Fda-Approved Test And Who Have Received At Least 2 Prior Systemic Therapies. Tazverik Is Indicated For The Treatment Of Adult Patients With R/r Fl Who Have No Satisfactory Alternative Treatment Options. These Indications Are Approved Under Accelerated Approval Based On Overall Response Rate And Duration Of Response [See Clinical Studies ( 14.2 )]. Continued Approval For These Indications May Be Contingent Upon Verification And Description Of Clinical Benefit In A Confirmatory Trial(S). |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Tazemetostat Hydrobromide |